{"classes":[{"categories":[{"measurements":[{"comment":"N=2: Geometric mean and Geometric Coefficient of Variation were not calculated, individual values reported:1056 ng/mL and 570 ng/mL.","groupId":"OG000","spread":"NA","value":"NA"},{"comment":"N=1: Geometric mean and Geometric Coefficient of Variation were not calculated, individual values reported: 865 ng/mL.","groupId":"OG001","spread":"NA","value":"NA"},{"comment":"N=2: Geometric mean and Geometric Coefficient of Variation were not calculated, individual values reported: 225 ng/mL and 116 ng/mL.","groupId":"OG002","spread":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"}],"units":"Participants"}],"description":"Average concentration after the first dose of LY3499446.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received high dose LY3499446 as oral monotherapy BID in 21-day cycles.","id":"OG000","title":"LY3499446 Phase 1 Cohort A1 (High Dose)"},{"description":"Participant received mid dose LY3499446 as oral monotherapy once QOD in 21-day cycles.","id":"OG001","title":"LY3499446 Phase 1 Cohort AO (Mid Dose)"},{"description":"Participants received low dose LY3499446 as oral monotherapy once QD in 21-day cycles.","id":"OG002","title":"LY3499446 Phase 1 Cohort A-2 (Low Dose)"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"All participants who have received at least one dose of study drug and had evaluable PK.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1: Predose, 0.5, 1, 1.5, 2, 3, 4, 8, 24 hours post-dose","title":"Phase 1: Pharmacokinetics (PK): Average Concentration of LY3499446","type":"SECONDARY","unitOfMeasure":"nanograms per milliliter (ng/mL)"}